The invention provides compositions and methods for treatment of Alzheimers disease. Such methods entail administering agents that induce a beneficial immune and therapeutic response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimers disease. In certain preferred embodiments of such methods, a preferred agent is amyloid beta peptide in combination with Sphingosine-1-phosphate, preferably delivered in certain embodiments in a liposomal formulation.
